Image credit: Canva
About 90,000 new cases of brain and spinal cord tumors are diagnosed annually in the United States. Many people who have malignant tumors of the central nervous system have changes in certain genes (MYC or MYCN) that drive the development of their cancers. A clinical trial led by Marta Penas-Prado, M.D., M.Sc., Senior Clinician in the Neuro-Oncology Branch, is researching drug therapy for such tumors.
The trial will take place at the NIH Clinical Center in Bethesda, Maryland, and there is no cost for medical care received at the Clinical Center.
For more information, please contact the NCI Neuro-Oncology Branch Referral Group at NCINOBReferrals@mail.nih.gov or (866) 251-9686
Clinicaltrials.gov identifier: NCT06161519
NCI Protocol ID: IRB001534
Official Title : Phase I/II Trial of PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.
For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.
